RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.
 

A Dutch producer of active pharmaceutical ingredients (APIs) was put on notice to adopt more robust equipment cleaning practices and use better safeguards to prevent cross-contamination in a warning letter from the US Food and Drug Administration ...

See More

Updated 01 July with new information on Paxlovid, Evusheld, molnupiravir, Regkirona and ivermectin.

See More

Regulatory professionals need a new guide to medical device regulations. We just wrote one.

See More

Heeding the advice of its expert advisory committee, the US Food and Drug Administration (FDA) on Thursday recommended the inclusion of an Omicron BA.4/5 spike protein component in modified COVID-19 vaccine boosters for the upcoming fall and winte...

See More

The US Food and Drug Administration (FDA) this week issued a sweeping draft guidance intended to help stakeholders incorporate patient experience data through the use of meaningful clinical outcome assessments (COAs).

See More

Racial, ethnic and sociodemographic disparities that are present in clinical trials and compassionate use agreements for cancer immunotherapy during the pre-approval period are reduced, but not eliminated after the US Food and Drug Administration ...

See More

MHRA proposed a slate of medtech reforms considering the Cumberlege Review and the opportunity presented by Brexit. The proposals were intended to improve patient safety, increase transparency, more closely align the UK with international practice...

See More

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

See More

A global regulatory group is seeking industry participants for two pilot programs exploring a common regulatory framework for assessing manufacturing facilities in hybrid inspections and for reviewing postapproval changes.  

See More

Both industry and clinicians asked the US Food and Drug Administration (FDA) for clarification related to the evaluation of cellular starting materials in its draft guidance on chimeric antigen receptor (CAR) T cell product development.

See More

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

See More

The former top US Food and Drug Administration (FDA) cybersecurity expert says it’s only a matter of time before disaster strikes in the form of a medical device exploit that could harm patients. To get ahead of the problem, he said the agency nee...

See More